Vascular Pharmacology of Mokuboito (Mu-Fang-Yi-Tang) and Its Constituents on the Smooth Muscle and the Endothelium in Rat Aorta by Nishida, Seiichiro & Satoh, Hiroyasu
Advance Access Publication 6 December 2006 eCAM 2007;4(3)335–341
doi:10.1093/ecam/nel097
Original Article
Vascular Pharmacology of Mokuboito (Mu-Fang-Yi-Tang) and Its
Constituents on the Smooth Muscle and the Endothelium in Rat
Aorta
Seiichiro Nishida and Hiroyasu Satoh
Department of Pharmacology, Division of Crude and Herbal Medicine, Nara Medical University,
Kashihara, Nara 634-8521, Japan
Pharmacological actions of Mokuboito and its constituents (Sinomenium acutum and sinomenine) on rat
aorta were examined. Mokuboito and S. acutum at lower concentrations (0.03–1 mgml
 1) contracted the
non-loaded aorta, but at higher concentrations (1–3 mg ml
 1), reversed to dilate it. The vasoconstriction
was blocked by phentolamine (10 mM). Sinomenine failed to exhibit the vasoconstriction. On the other
hand, Mokuboito and S. acutum dilated the NE (5 mM)-induced vasoconstriction: at 3 mg ml
 1,b y
98.9 ± 2.5% (n ¼ 6, P < 0.01) and 97.0 ± 4.8% (n ¼ 6, P < 0.01). Vasorelaxation induced by Mokuboito
and S. acutum was attenuated by indomethacin, L-NMMA and nicardipine. Propranolol decreased the
vasorelaxation induced by Mokuboito, but not by S. acutum. Sinomenine also relaxed the constriction
and at 100 mM, by 68.8 ± 5.1% (n ¼ 7, P < 0.01). This vasorelaxation was attenuated by indomethacin,
L-NMMA and nicardipine, and also by propranolol. Therefore, these results indicate that Mokuboito and
its constituents exert both vasodilating actions mediated by endothelium-dependent mechanisms (PGI2
and NO from endothelium) and by endothelium-independent mechanisms (Ca
2þ influx control on
smooth muscle cells). Simultaneously, Mokuboito and S. acutum cause the vasoconstrictions mediated
through a-adrenoceptor stimulation, but not sinomenine. Also, Mokuboito and sinomenine possess b-
adrenoreceptor stimulating action, but not S. acutum.
Keywords: a- and b-adrenoceptors – Ca
2þ channel – EDRF – endothelium – Mokuboito – PGI2 – rat
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Introduction
Mokuboito (Mu-Fang-Yi-Tang), a kind of Kampo formula-
tions, has clinically been used for heart failure (1). It has been
shown that Mokuboito improves heart failure symptom, and
reducesthelevelofNewYorkHeartAssociation(NYHA)class
and plasma brain natriuretic peptide (BNP) concentration (2).
Mokuboito consists of 4 g Sinomeni Caulis et Rhizoma
(rhizome of Sinomenium acutum Rehdler et Wilson), 3 g
Cinnamomi Cortex (bark of Cinnamomum cassia Blume), 3 g
Ginseng radix (roots of Panax ginseng C. A. Meyer) and 10 g
Gypsum Fibrosum. Cinnamon cortex and its constituent
(cinnamic aldehyde) have been reported to have some
pharmcological effects; antiplatelet and anti-inflammatory
effects (3,4) and also antitumor activity (5). Panax ginseng
possesses many pharmacological effects and exhibits some
clinical efficicacies: care of general fatigue and stress (6,7). In
addition, it possesses immunomodulating (8,9) and neuro-
protective actions (10). Finally, Gypsum has been used as one
of the crude drugs in traditional Kampo medicine. Its pharma-
cological is reasonably clear, but previous reports have shown
that Gypsum prevents the thermogenesis effect induced by
ephedrine at an ambient temperature of 22 C (11).
S. acutum has traditionally been considered as a modulator
of body’s fluid and been applied for disturbances of body
fluids. Sinomenine is one of alkaloids extracted from
S. acutum (12). As an antirheumatic and anti-inflammatory
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rheumatoid arthritis (13,14). In basic researches, sinomenine
reduces the production of prostagrandin (PG) E2 and nitric
oxide (NO) from macrophages (15). Sinomenine reduces
inflammatory parameters and attenuates proliferation of
synovial fibroblasts in rat adjuvant arthritis models (14). In
addition, acute and chronic cardiac allograft ejections are
blocked by the immunomodulatory effects of sinomenine (16).
More recently, Satoh (17) has demonstrated that Mokuboito
and its constituents exhibit cardiac electropharmacological
actions and exert the conservative actions on cardiomyocytes.
These findings indicate that Mokuboito, S. acutum and
sinomenine exert effective pharmacological actions that can
improve chronic heart failure via the recovery of cardiac
functions.
In general, the treatment of heart failure consists of (i)
reducing workload of heart, (ii) protection of cardiomyocytes
and (iii) restriction of sodium and fluid control. For reduction
of the preload and afterload, the dilations of arterioles and
veins are required in the case of elevated filling pressures and
reduced cardiac output. We demonstrated that S. acutum
dilated vasoconstrictions (18). Therefore, Mokuboito, S.
acutum or sinomenine may treat heart failure not only by
improvement of cardiac effects but also by controlling the
tension of blood vessels. In these experiments, therefore, we
wanted to elucidate in more detail the vascular pharmacology
of Mokuboito, S. acutum and sinomenine, using rat aorta rings.
Methods
All experiments were carried out, according to the guidelines
laid down by the Nara Medical University Animal Welfare
Committee, and also under the terms of the Declaration of
Helsinki.
Male Wistar rats (4–10 weeks old) were anesthetized with
ether, and euthanized by exsanguination. The thoracic aorta
was quickly removed, and the isolated aorta cut into rings of
3 mm in length. The rings were suspended between two
triangular-shaped stainless steel stirrups in a jacketed organ
chamber filled with 20 ml modified Krebs–Henseleit solution.
The modified Krebs–Henseleit solution was comprised of
(in mM); 118 NaCl, 4.6 KCl, 1.2 MgSO4, 1.2 KH2PO4, 11.1
glucose, 27.2 NaHCO3, 0.03 Na2-ethylenediaminetetraacetic
acid (EGTA) and 1.8 CaCl2. The chamber solution was kept at
36.5 C and oxygenated with 95% O2 and 5% CO2. The lower
stirrup was anchored and the upper stirrup was attached to a
force-displacement transducer (Nihon Kohden TB-652T,
Tokyo, Japan) to record the isometric force. All rings were
stretched to generate a resting tension of 1.2 g, which was
optimal for contractions with a-adrenergic receptor agonist.
After 40 min of resting, norepinephrine (NE, 5 mM) was added
to the tissue bath. After the contractile response became
steady, the drugs were cumulatively administrated into the
bath solution. The effects of each concentration of the drugs
were measured 6–10 min after the responses became steady.
The responses were analyzed as a percentage change from the
value before the application of drugs.
Mokuboito, the kampo medicine used in this study, has been
supplied from Tsumura Co., Ltd (Tokyo) as a spray-dried
powder which was extracted with boiling water of a mixture of
respective ground raw materials, 4 g of Sinomeni Caulis et
Rhizoma (rhizome of S. acutum Rehdler et Wilson), 3 g of
Cinnamomi Cortex (bark of C. cassia Blume), 3 g of Ginseng
radix (roots of Panax ginseng C. A. Meyer) and 10 g of
Gypsum Fibrosum. This Mokuboito is exactly equaled to TJ-
36 provided by Tumura Co., Ltd. S. acutum extract was also
prepared as a spray-dried powder extracted with boiling water
of a ground raw material of Sinomeni Caulis et Rhizoma
(rhizome of S. acutum Rehdler et Wilson).
The other drugs used were sinomenine (7,8-didehydro-
4-hydroxy-3,7-dimethoxy-17-methylmorphinae-6-one), indo-
methacin and staurosporine (Wako Chemical, Kyoto, Japan).
NG-monomethyl-l-arginine acetate (L-NMMA), and nicardi-
pine (Sigma Chemical Co., St Louis, MO, USA) were also
used.
All values are represented as means ± SEM. The differences
of data in mean values were analyzed by the Student’s t-test
and ANOVA followed by post hoc tests (Dunn–Bonferonii
test), and a P-value of <0.05 was considered significant.
Results
Significant Vasorelaxation Induced by Mokuboito
The aorta ring strip of rat exhibited a strong constriction after
an initial application of 5 mM NE. Mokuboito applications
(0.03–3 mg ml
 1) markedly relaxed the constriction induced
by NE in a concentration-dependent manner, as shown in
Table 1. The significant relaxation was produced at concentra-
tions of over 0.1 mg ml
 1. Mokuboito at 3 mg ml
 1 decreased
it by 98.9 ± 2.5% (n ¼ 7, P < 0.001). To examine the
involvement with endothelium-dependent relaxation, 40 min
Table 1. Vasorelaxations induced by Mokuboito and Sinomenium acutum on NE-induced vasoconstriction: comparison with Mokuboito and a main
constituent (S. acutum)
n 0.03 0.1 0.3 1 3 mg ml
 1
Mokuboito 7 0.90 ± 0.72 5.0 ± 0.5* 9.2 ± 1.6* 35.1 ± 7.1** 98.9 ± 2.5***
Sinomenium acutum 6 1.76 ± 0.78* 5.1 ± 0.54* 13.4 ± 1.7* 45.6 ± 7.1** 97.0 ± 4.8***
Values (%) represent mean ± SEM.
*P < 0.05, **P < 0.01, ***P < 0.001, with respect to control value.
336 Vasomodulation induced by Mokuboitopretreatment with L-NMMA (a non-selective NO synthesis
inhibitor) was carried out. In the presence of L-NMMA (100
mM), the vasorelaxation induced by 0.03 and 0.1 mg ml
 1
Mokuboito was significantly attenuated from 5.0 ± 0.5% (n ¼
7) and 9.2 ± 1.6% (n ¼ 7) to 2.3 ± 1.3% (n ¼ 5, P < 0.01) and
3.4 ± 1.7% (n ¼ 5, P < 0.05), respectively (Fig. 1). Also,
Mokuboito was applied in the presence of indomethacin (an
inhibitor of prostanoid production). Indomethacin (10 mM)
significantly reduced the vasorelaxation of Mokuboito at 1 and
3m gm l
 1 from 35.1 ± 7.1% (n ¼ 7) and 98.9 ± 2.5% (n ¼ 7)
to 11.6 ± 8.1% (n ¼ 5, P < 0.01) and 57.5 ± 14.4% (n ¼ 5, P <
0.01), respectively (Fig. 1). In addition, the vasorelaxation was
also examined in the presence of nicardipine to elucidate the
involvement with Ca
2þ channels on the vascular smooth
muscle cells. Nicardipine (0.1 mM) attenuated the vasorelaxa-
tion at 3 mg ml
 1 Mokuboito to 85.3 ± 3.7% (n ¼ 5, P < 0.01).
The involvement with b-adrenoreceptor stimulation (cAMP-
dependence) was also examined. Mokuboito (0.03–1 mg ml
 1)
further constricted the NE-induced constrictions in the
presence of 0.3 mM propranolol (Fig. 2A). However, additional
application of 3 mg ml
 1 Mokuboito reversely dilated the
vasoconstriction to almost control level. The summarized data
are presented in Fig. 2B.
Mokuboito Produced Vasoconstriction at Lower
Concentrations
Using a non-loaded aorta (not pretreated with NE), Mokuboito
was cumulatively administrated to examine whether it caused
vasoconstriction (Fig. 3A). Mokuboito at lower concentrations
of 0.03–0.3 mg ml
 1 produced a vasoconstriction on the
non-loaded aorta. At 1 mg ml
 1, however, Mokuboito reversed
to the vasorelaxation. Furthermore, the vasoconstriction
induced by Mokuboito (at 0.03–0.3 mg ml
 1) was blocked
by 10 mM phentolamine (a-adrenoceptor blocker) (Fig. 3B and
C). Mokuboito involved with b-adrenoceptor stimulation, as
mentioned above. These results indicate that Mokuboito has
both pharmacological characteristics for a vasorelaxation via
b-adrenoreceptor stimulation and a vasoconstriction via a-
adrenoreceptor stimulation.
S. acutum Induced a Concentration-Dependent
Vasorelaxation
S. acutum also caused a concentration-dependent vasorelaxa-
tion on the NE-induced vasoconstriction (Table 1). S. acutum
at 3 mg ml
 1 dilated the constriction by 97.0 ± 4.8% (n¼ 6). In
the presence of L-NMMA (100 mM), S. acutum (at 0.1–3 mg
ml
 1) also significantly decreased the relaxation (Fig. 4). The
vasorelaxation at 3 mg ml
 1 was attenuated from 97.0 ± 4.8%
(n ¼ 6) to 84.9 ± 1.9% (n ¼ 5, P < 0.05). Indomethacin (10
mM) and nicardipine (0.1 mM) also attenuated the S. acutum-
induced relaxation. However, propranolol did not affect it.
As shown in Fig. 3A, similar vasoconstriction on the non-
loaded rat aorta was produced by 0.03–1 mg ml
 1 S. acutum.
At 3 mg ml
 1S. acutum reversedto dilate the vasoconstriction,
like Mokuboito and the vasoconstriction is completely blocked
by 10 mM phentolamine (Fig. 3B–D).
Sinomenine Never Produced Vasoconstriction
Sinomenine caused no effects on non-loaded aorta and never
produced vasoconstrictive effect. Sinomenine (0.1–100 mM)
potently relaxed the constriction induced by NE in a
concentration-dependent manner, as shown in Table 2. Under
the pretreatment with 100 mM L-NMMA, the vasorelaxation
induced by 100 mM sinomenine was attenuated from 68.8 ±
5.1% (n ¼ 6) to 25.3 ± 2.3% (n ¼ 5, P < 0.01) (Fig. 5).
Indomethacin (10 mM) also strongly reduced it to 37.1 ± 9.3%
(n ¼ 5, P < 0.001). The relaxation of sinomenine (0.1–100
mM) was significantly attenuated by nicardipine; at 100 mM
sinomenine from 68.8 ± 5.1% (n ¼ 6) to 35.5 ± 6.9% (n ¼ 5, P
< 0.001). Propranolol (0.3 mM) also significantly attenuated
the sinomenine (1–100 mM)-induced relaxation. The vaso-
relaxation at 100 mM sinomenine was attenuated to 45.2 ±
4.2% (n ¼ 5, P < 0.01).
Discussion
The results from the present experiments were as follows: (i)
Mokuboito, S. acutum and sinomenine exhibited
concentration-dependent vasorelaxation on NE-induced vaso-
constriction, (ii) L-NMMA and indomethacin significantly
attenuated the vasorelaxation induced by Mokuboito, S.
acutum and sinomenine, (iii) nicardipine also decreased
them, (iv) Mokuboito and S. acutum at lower concentrations
caused vasoconstrictions on the non-loaded aorta, but at high
concentrations oppositely dilated the vasoconstriction induced
Figure 1. Modulation of concentration-dependent relaxations of Mokuboito
in the presence of several inhibitors. Symbols used are control (filled circles,
n ¼ 7) and the pretreatments with L-NMMA (triangles, n ¼ 5), indomethacin
(squares, n ¼ 5) and nicardipine (diamonds, n ¼ 5). Values (%) represent
mean ± SEM. *P < 0.05, **P < 0.01, with respect to control value.
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vasoconstriction on the non-loaded aorta, (vi) in the presence
of propranolol, Mokuboito at lower concentrations reinforced
further the NE-induced vasoconstriction, but at 3 mg ml
 1 it
was reversed to decrease the vasoconstriction and (vii)
propranolol also attenuated sinomenine-induced vasorelaxa-
tion, but caused no effects on the vasorelaxation induced by
S. acutum.
Mokuboito possessed the vasoconstrictive effect on the
non-loaded rat aorta. Mokuboito at 0.03–0.3 mg ml
 1
caused vasoconstriction, but at 1 mg ml
 1 decreased the
vasoconstriction induced by the lower concentrations and
then recovered to control level. Since the vasoconstriction
was blocked by phentolamine, Mokuboito produced the
vasoconstriction mediated through a-adrenoceptors. Under
the pretreatment with propranolol, also, Mokuboito at lower
concentrations (0.03–1 mg ml
 1) reinforced further the
NE-induced vasoconstrictions. Therefore, these results indic-
ate that Mokuboito possesses both b- and a-adrenoceptor
stimulating actions. At lower concentrations of Mokuboito,
a-adrenoceptor stimulating action overcomes its b-
adrenoceptor stimulating action, resulting in an appearance
of only vasoconstriction on the non-loaded rat aorta. At
higher concentrations, the other actions including b-
adrenoceptor stimulation of Mokuboito were exerted, and
as a result, vasodilation would be produced.
Both L-NMMA and indomethacin attenuate vasorelaxation
induced by Mokuboito. Thus, Mokuboito exerts the vasor-
elaxation by the secretions of endothelium-derived
relaxation factor (EDRF, that is NO) and also of PGI2.
Furthermore, nicardipine attenuated the vasorelaxation
induced by Mokuboito, resulting from Ca
2þ channel inhibitory
action.
S. acutum also possesses the vasoconstrictive effect on the
non-loaded rat aorta; and Sinomenine acutum at 3 mg ml
 1
reversed to decrease the vasoconstriction. Similarly, the
vasoconstriction was attenuated by phentolamine, and the
vasorelaxation was reduced by propranolol. S. acutum never
caused vasoconstriction in the presence of propranolol.
Therefore, these results indicate that S. acutum also possesses
both b- and a-adrenoceptor stimulating actions. However,
a-adrenoceptor stimulating action is not as strong as Moku-
boito, and the vasoconstriction does not appear even under the
pretreatment with propranolol.
Mokuboito has b- and a-stimulating actions. Since both
a- and b-adrenoceptors are widespread in the whole body,
Mokuboito might stimulate both adrenoceptors. In our study, it
is still unclear whether Mokuboito, S. acutum and sinomenine
have more selective affinity to a- and b-adrenoceptors. The a-
stimulating effects of Mokuboito and S. acutum might be
mediated through a1-adrenoceptor on adrenergic nerve
terminals.
Figure 2. Modulation of vasodilating action of Mokuboito by the pretreatment with propranolol. (A) Actual recording for the effects of Mokuboito in 0.3 mM
propranolol. (B) Summary for the constrictive force at different concentrations of Mokuboito in the presence of propranolol. *P < 0.05, **P < 0.01, ***P < 0.001,
with respect to control value.
338 Vasomodulation induced by MokuboitoSinomenine possesses the strong vasodilating action (19).
However, sinomenine never causes the vasoconstrictive effect.
The vasorelaxation was similarly attenuated by L-NMMA and
indomethacin. These results indicate that sinomenine also
produces EDRF and PGI2 releases. Furthermore, since
nicardipine inhibited the sinomenine-induced vasorelaxation,
the vasorelaxation is responsible for Ca
2þ channel inhibition.
The EDRF and PGI2 releases are activated by an increase of
cellular Ca
2þ ([Ca
2þ]i) in endothelium cells (20). The detailed
mechanisms for the endothelium-dependent relaxations are not
yet unclear. However, Mokuboito and the constituents would
increase [Ca
2þ]i in endothelium cells and then activate NOS
activity and PGI2 release. Thus, we conclude that Mokuboito,
S. acutum and sinomenine involve with EDRF and PGI2, and
regulate the Ca
2þ influx via L-type Ca
2þ channels on the cell
membrane of aortic smooth muscle.
Mokuboito consists of S. acutum (4 g), Cinnamon cortex
(3 g), Ginseng radix (3 g) and Gypsum (10 g). Sinomenine is
one of the constituents of S. acutum. It is estimated that
 66 mM sinomenine is contained in 1 mg ml
 1 of S. acutum,
corresponding to 2.2% (Pharmaceutical Institute of Tsumura
Co.). S. acutum at 1 mg ml
 1 caused the vasorelaxation by
 46%. On the other hand, sinomenine at 66 mM estimated
vasorelaxation by  60%. The relaxing strength of S. acutum
and sinomenine is not so different. Since both compounds may
cause the vasorelaxation by similar mechanisms, sinomenine
may play a main role for the vasorelaxation induced by
S. acutum. In the presence of propranolol, however, there were
Figure 3. Vasomodulation induced by Mokuboito and Sinomenium acutum of the non-loaded (resting state of) aortic smooth muscle. (A) Vasoconstriction and
vasodilation induced by the compounds, administrated cumulatively. (B) Blockade of vasoconstriction of Mokuboito and S. acutum by 10 mM phentolamine. (C)
Modulation by phentolamine of the vasoconstriction induced by Mokuboito. The bars are Mokuboito in the absence (white column, n ¼ 7) and in the presence of
10 mM phentolamine (black column, n ¼ 5). Values (g) represent mean ± SEM. **P < 0.01, with respect to control value. (D) Effects of phentolamine on the
vasoconstriction induced by S. acutum. The bars mean S. acutum alone (white column, n ¼ 5) and S. acutum in 10 mM phentolamine (black column, n ¼ 5). Values
(g) represent mean ± SEM. **P < 0.01, with respect to control value.
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S. acutum causes vasoconstriction, whereas sinomenine has
no effect. This difference cannot be explained now, but there
could be a component in S. acutum different from sinomenine.
Although sinomenine may be considered as a key constitu-
ent of S. acutum, we cannot necessarily explain the entire
pharmacological effects of Mokuboito; because sinomenine is
only 2.2% in S. acutum, and only 0.6% in Mokuboito. Thus,
there may be a great difference between the pharmacological
potencies of Mokuboito and sinomenine included in Moku-
boito. S. acutum include only 20% in Mokuboito, but the
potencies of Mokuboito and S. acutum are almost similar.
Cinnamon cortex and Ginseng radix also possess vasodilating
effects (21,22). Therefore, the complex interactions among
S. acutum, Cinnamon cortex and Ginseng radix would produce
the pharmacological effects of Mokuboito as a whole. The
whole effect as a Mokuboito is absolutely not a simple sum of
each effect induced by its constituents.
Mokuboito istraditionally used fordyspnea andedema (1,2).
Thus, Mokuboito may be expected as one of the therapeutic
drugs for heart failure. Most recently, Satoh (17) has demon-
strated the effective modulation of cardiac ion channels by
Mokuboito, S. acutum and sinomenine. Sinomenine inhibits
ICa, and simultaneously produces the Ik decrease in cardio-
myocytes, resulting in the APD prolongation. And sinomenine
also exhibits an antiarrhythmic action on dysrhythmias under
Ca
2þ-overloaded conditions. The antiarrhythmic effect would
be due to the APD prolongation and the [Ca
2þ]i reduction by
the inhibitions in ICa and INa channels.
Mokuboito, S. acutum and sinomenine have multiple vaso-
dilating mechanisms. The vasodilating actions are expected as
one of the great useful tools for heart failure, and can regulate
the preload and afterload of cardiovascular systems. The
reduction of both loads is the essential therapeutic strategies
for heart failure. Therefore, the vasodilating actions by
Mokuboito, S. acutum and sinomenine can sufficiently
improve cardiac functions by reduction of the preload and
afterload against heart failure.
In this study, Mokuboito, S. acutum and sinomenine may
regulate the Ca
2þ influx via L-type Ca
2þ channel, consistent
with the previous report (17). This may be a Ca
2þ channel
inhibitor, because the effect of sinomenine was attenuated
under the conditions of low Ca
2þ extracellular concentration
(19), as well as in the presence of nicardipine. Under ischemia
Figure 5. Modulation of the vasorelaxations induced by sinomenine in the
presence of some inhibitors. Symbols used are control (filled circles, n ¼ 7),
propranolol (open circles, n ¼ 5), L-NMMA (triangles, n ¼ 5), nicardipine
(squares, n ¼ 5) and indomethacin (diamonds, n ¼ 5). Values (%) represent
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, with respect to control
value.
Figure 4. Modulationofthevasorelaxation inducedbySinomeniumacutumin
the pretreatment with several inhibitors. Symbols used are control (filled
circles, n ¼ 6), propranolol (open circles, n ¼ 6), L-NMMA (triangles, n ¼ 6),
nicardipine (squares, n ¼ 6) and indomethacin (diamonds, n ¼ 6). Values (%)
represent mean ± SEM. *P < 0.05, with respect to control value.
Table 2. Modulation by sinomenine of the relaxation on NE-induced vasoconstriction: pharmacology of a major constituent, sinomenine
Sinomenine
n 0.1 0.3 1 3 10 30 100 mM
6 6.1 ± 2.0* 12.5 ± 2.5** 20.5 ± 2.2** 25.1 ± 2.2** 44.2 ± 4.4*** 52.8 ± 6.0*** 68.8 ± 5.1***
Values (%) represent mean ± SEM.
*P < 0.05, **P < 0.01, ***P < 0.001, with respect to control value.
340 Vasomodulation induced by Mokuboitoand heart failure, cellular Ca
2þ overload of heart muscles
elicits arrhythmias and dysfunctions (23,24). The Ca
2þ influx
control may regulate cellular Ca
2þ, overload cardiomyocytes
and produce the protective actions for Ca
2þ-overloaded cells
(23). Thus, Mokuboito, S. acutum and sinomenine might
protect cell damages of heart muscles via regulation of [Ca
2þ]i,
and as a result, would exert a cardioprotective action. Further
experiments are needed to elucidate in more detail the
mechanisms for pharmacological actions.
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